

APPLICANT(S): YEDGAR, Saul et al.
SERIAL NO.: 10/790,182
FILED: March 2, 2004
Page 2

AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. *(Currently amended)* A method of treating a subject suffering from an intestinal disease, comprising the step of administering to ~~[[a]]~~ said subject an effective amount of a lipid or phospholipid moiety bonded via an amide or ester linkage to a ~~physiologically acceptable monomer, dimer, oligomer, or polymer~~ glycosaminoglycan, thereby treating ~~[[the]]~~ said subject suffering from said ~~an~~ intestinal disease.

2. *(Original)* The method of claim 1, wherein said intestinal disease is Crohn's disease, ulcerative colitis, immuno-inflammatory intestinal injury, drug-induced enteropathy, ischemia-induced intestinal injury or any combination thereof.

3-6. *(Cancelled)*

7. *(Original)* The method of claim 1, wherein said phospholipid moiety is phosphatidylethanolamine.

8. *(Currently amended)* The method of claim 1, wherein Use of a said lipid or phospholipid moiety bonded to a physiologically acceptable monomer, dimer, oligomer, or polymer glycoaminoglycan is administered as part in the preparation of a pharmaceutical composition for treating a subject afflicted with an intestinal disease.

9-21. *(Cancelled)*

22. *(New)* The method of claim 1, wherein said glycosaminoglycan is hyaluronic acid.

23. *(New)* The method of claim 1, wherein said glycosaminoglycan is heparin.

24. *(New)* The method of claim 1, wherein said glycosaminoglycan is chondroitin sulfate.

25. *(New)* The method of claim 24, wherein said chondroitin sulfate is chondroitin-6-sulfate, chondroitin-4-sulfate, or a derivative thereof.

APPLICANT(S): YEDGAR, Saul et al.
SERIAL NO.: 10/790,182
FILED: March 2, 2004
Page 3

26. (New) The method of claim 7, wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine.
27. (New) The method of claim 7, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
28. (New) The method of claim 1, wherein said intestinal disease is immuno-inflammatory intestinal injury.
29. (New) The method of claim 1, wherein said intestinal disease is Crohn's disease.
30. (New) The method of claim 1, wherein said intestinal disease is ulcerative colitis.